Our findings provide evidence α7nAChR agonists attenuate diabetes-induced kidney injury in the db/db model and could serve as a novel approach to ameliorating the progression of DN in patients with T2DM. This evidence concerns the gene CHRNA7 and liver dysplastic nodule.